Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

FAITH

Financiado

Cerrado

Fatty liver Nano Antibody Therapy FAITH

Changes in life-style and nutrition have increased the incidence of obesity/overweight and metabolic syndrome resulting in a pathology called Non-alcoholic fatty liver disease (NAFLD). Currently, 130 million people in Western coun... ver más

31/01/2022

GERMAN CANCER RESE...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-01-31

ERC-2020-POC: Call for proposals for ERC Proof of...

I+D

Cerrada hace 5 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

GERMAN CANCER RESEARCH CENTE...

150.00K€ | Lider

ULTRACONGELADOS VIRTO

397.80K€ | Participante

Proyectos interesantes

RTI2018-094734-B-C21

Medical Technol...

Nanotechnology

230K€ Cerrado

PRE2020-094885

Nanotechnology

Medical Technol...

99K€ Cerrado

CONNECT-2-CLINIC

Medical Technol...

Nanotechnology

150K€ Cerrado

PRE2019-088097

Medical Technol...

Nanotechnology

98K€ Cerrado

PDC2022-133780-C22

Medical Technol...

Nanotechnology

75K€ Cerrado

RYC-2010-07249

Medical Technol...

Biomedical Imag...

192K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 18 meses Fecha Inicio: 2020-07-09
Fecha Fin: 2022-01-31

Líder del proyecto

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Changes in life-style and nutrition have increased the incidence of obesity/overweight and metabolic syndrome resulting in a pathology called Non-alcoholic fatty liver disease (NAFLD). Currently, 130 million people in Western countries have NAFLD and this number is constantly increasing. A significant number of patients develop non-alcoholic steatohepatitis (NASH), fibrosis and subsequently liver cancer. At the same time no efficient therapeutics exist to treat NASH or NASH-liver cancer transition. We could demonstrate that infiltration and aggregation of platelets in the liver is the initial and the disease accompanying/maintaining process. Application of a conventional antiplatelet-therapy (APT) prevented or reverted established NASH in mice and men and abandoned subsequent liver cancer development in mouse models. Existing APT bear unwanted side effects and health issues. We identified the platelet-derived surface molecule GPIba as the critical mediator of platelet-derived immune activation, NASH and liver cancer. Using an antibody blocking the thrombin-binding site of GPIba, prevented established NASH, fibrosis and liver cancer without affecting hemostasis (Malehmir et al. 2019 Nature Medicine). The identified novel strategy differentiates itself from all other approaches to treat NASH due to some unique application opportunities: (I) no necessity to change patients’ nutritional habits, resulting in a high acceptance on the patient´s side, (II) no systemic immunosuppression of the patients´ immune system and (III) circumventing unwanted severe side effects of conventional APT by decoupling platelet-derived inflammatory function from platelet-derived aggregation/hemostasis. We intend (1) to produce nanobodies/antibodies that functionally block the human thrombin binding site of GPIba, (2) to confirm the therapeutic activity in preclinical NASH models carrying a humanized GPIba and (3) to lay the ground for necessary subsequent steps towards the market.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores